Biotechnology company Oxford BioMedica PLC (OXB.LN) Wednesday said it has enough money to fund its drug programs until 2012, as it gears up to begin new clinical trials.

Later this year, Oxford BioMedica plans to start trials of experimental medicines for eye conditions and a new trial of its cancer vaccine TroVax.

The new Phase II trial will test the vaccine in prostate cancer patients, and follows an earlier disappointment in a trial for kidney cancer.

The prospects for cancer vaccines as a class of drugs received a boost last month when the U.S. Food and Drug Administration approved Provenge, developed by Dendreon Corp. (DNDN), as a treatment for prostate cancer.

Celldex Therapeutics Inc. (CLDX) and GlaxoSmithKline PLC (GSK.LN) are also developing similar therapies, which are designed to stimulate the body's immune system to fight the disease.

Oxford BioMedica added Wednesday discussions with potential partners for late-stage testing of TroVax and experimental Parkinson's disease treatment ProSavin are ongoing.

The company is due to report data from two studies of ProSavin at a scientific conference in June.

It said it had GBP25.3 million in cash at the end of 2009.

-By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Celldex Therapeutics Charts.
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Celldex Therapeutics Charts.